Gilead Sciences Inc GILD

Gilead Sciences, Inc. es una empresa biofarmacéutica basada en la investigación que descubre, desarrolla y comercializa medicamentos en áreas de necesidades médicas no cubiertas. La cartera de productos de la compañía y su pipeline de medicamentos en investigación incluyen tratamientos para el Virus de Inmunodeficiencia Humana/Síndrome de Inmunodeficiencia Adquirida (VIH/SIDA), enfermedades hepáticas, cáncer, enfermedades inflamatorias y respiratorias, y condiciones cardiovasculares. Sus productos para pacientes con VIH/SIDA incluyen Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost y Vitekta. Sus productos para pacientes con enfermedades hepáticas incluyen Vemlidy, Epclusa, Harvoni, Sovaldi, Viread y Hepsera. Ofrece Zydelig a pacientes con enfermedades de hematología/oncología. Sus productos para pacientes con diversas enfermedades cardiovasculares incluyen Letairis, Ranexa y Lexiscan. Sus productos para diversas enfermedades de inflamación/respiratorias incluyen Cayston y Tamiflu. Tenía operaciones en más de 30 países, hasta el 31 de diciembre de 2016.

Con 7 acciones de GILD (USD 1.009,34) habrías recibido USD 22,75 en dividendos en los últimos 12 meses.

• Zacks Investment Research 1 oct

  Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

  Gilead Sciences (GILD), an HIV and hepatitis C drugmaker, is a trending stock with mixed fundamentals. The company maintains a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the broader market. While Gilead has beaten consensus estimates in the last four quarters and shows modest revenue growth forecasts of 4.4% and 6.1% for the current and next fiscal years, earnings estimates remain challenged with a projected -105.9% year-over-year change for the current fiscal year. The stock is valued at par with its peers.

  

• Zacks Investment Research 30 sept

  Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors

  Gilead Sciences declined 1.21% on September 30, 2026, underperforming the S&P 500's 0.25% loss. The HIV and hepatitis C drugmaker faces headwinds with projected quarterly EPS down 12.96% year-over-year, though revenue is expected to rise slightly by 0.3%. The company holds a Zacks Rank #3 (Hold) rating with consensus EPS estimates revised 2.2% lower over the past month.

  

• The Motley Fool 22 sept

  Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

  The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.

  

• GlobeNewswire Inc. 22 sept

  Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial Opportunities

  A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.

  

• Zacks Investment Research 18 sept

  Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?

  AstraZeneca's stock has declined following several late-stage pipeline failures including Wainua in ATTR-CM, Ultomiris in HSCT-TMA, volrustomig in NSCLC, and Etcamah in breast cancer. However, the company maintains a broad pipeline with over 20 expected high-value readouts in the next 18 months, particularly in oncology. The stock trades at a reasonable valuation of 16.29x forward earnings, below industry average, though 2026-2027 earnings estimates have been revised downward.